Author: TreatSMA
Cambridge University Hospital continues to deny free life-saving treatment based on age
As you know our mission is treatment for all, and we have continued this fight by exposing Cambridge University Hospitals of their continued age discrimination against those with Spinal Muscular Atrophy. Equal access to health is the very tenant of the NHS yet CUH seem to feel otherwise.
Cambridge University Hospitals denies free life-saving treatment due to age, for the second time!
Cambridge University Hospitals (CUH) is regarded as one of the most reputable medical institutions worldwide and provides specialist services to many conditions nationally and internationally, including being a Neuromuscular Centre of Excellence as awarded by MDUK. Therefore, it begs the question, why, when the FDA, MHRA and most other Neuromuscular Centres across the country are…
Pre-approval access programme to risdiplam in the UK
Update on Roche’s pre-approval access programme to risdiplam and how it will be implemented in the UK
FDA approves Zolgensma, the first gene replacement therapy for SMA
The gene therapy drug Zolgensma (AVXS-101) receives FDA approval to treat spinal muscular atrophy in children below 24 months.
Gene therapy works wonders in children with SMA type 2
AveXis presented data that shows astonishing efficacy of AVXS-101 in SMA type 2 children
Questions and answers about Spinraza in the UK
TreatSMA anwers the most common questions regarding access to Spinraza treatment
Press release on NICE decision to recommend Spinraza treatment
Our official press release on NICE decision to recommend Spinraza
Spinraza will be available on the NHS for everyone!
Spinraza® has been recommended as a standard NHS treatment for all patients with spinal muscular atrophy in England and Wales.